Trial Profile
The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- 11 Dec 2015 New trial record